Brief: Volixibat Granted Breakthrough Therapy Designation For Cholestatic Pruritus In Primary Biliary Cholangitis
10/10/2024 13:33
Oct 10 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O :
* VOLIXIBAT GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR
CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS
* MIRUM PHARMACEUTICALS INC: CONFIRMATORY PORTION OF STUDY
IS
ONGOING WITH COMPLETION OF ENROLLMENT EXPECTED IN 2026
Source text for Eikon: ID:nBw6MwCBsa
Further company coverage: MIRM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX